Corient Private Wealth LLC Acquires 10,895 Shares of GSK plc (NYSE:GSK)

Corient Private Wealth LLC increased its stake in shares of GSK plc (NYSE:GSK - Free Report) by 12.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,344 shares of the pharmaceutical company's stock after buying an additional 10,895 shares during the quarter. Corient Private Wealth LLC's holdings in GSK were worth $3,258,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Indiana Trust & Investment Management Co grew its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Crews Bank & Trust bought a new stake in GSK in the 4th quarter worth about $26,000. ST Germain D J Co. Inc. increased its stake in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after buying an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC bought a new position in shares of GSK during the 4th quarter worth approximately $32,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on GSK. Morgan Stanley assumed coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.25.

Remove Ads

GSK Stock Performance

GSK stock traded up $0.08 during trading on Tuesday, hitting $38.65. The stock had a trading volume of 5,835,438 shares, compared to its average volume of 4,348,173. The stock's 50 day moving average is $36.90 and its two-hundred day moving average is $36.80. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The stock has a market cap of $80.00 billion, a price-to-earnings ratio of 24.31, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.07%. GSK's payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.